Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Immunotherapy for NSCLC: Recent advances and future directions

BGICC 2020

9 - 10 Jan 2020

Published: 27 Jan 2020

Views: 747

Rating:

Save

Prof Neal Ready - Duke University School of Medicine, Durham, USA

Prof Neal Ready speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about the different immunotherapies available to treat non-small-cell lung cancer (NSCLC).

He describes the recent advances in this area, including the selection of patients, based on their PDL-1 expression for example.

Prof Ready highlights the different types of therapy available for these patients and describes what the future looks like in this field.

Related Videos

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke

ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )

WCLC 2025: Latest in EGFR positive NSCLC

Prof Enriqueta Felip, Dr Antonio Passaro, Dr Alex Spira and Prof Ignacio Gil-Bazo

WCLC 2025: Latest in EGFR positive NSCLC ( Prof Enriqueta Felip, Dr Antonio Passaro, Dr Alex Spira and Prof Ignacio Gil-Bazo )

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

ELCC 2025: Latest in EGFR positive NSCLC

Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna Minchom

ELCC 2025: Latest in EGFR positive NSCLC ( Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna Minchom )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip

ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain

Biomarkers, predictive and prognostic factors of resistance to immunotherapy ( Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain )

More from ecancer